H.C. Wainwright recruits Kevin DeGeeter as pharmaceutical/biotech analyst

By Elaine Rigoli

Tampa, Fla., Feb. 14 - H.C. Wainwright & Co., Inc. announced Tuesday that Kevin DeGeeter has joined the company as a senior equity analyst focusing on Specialty Pharmaceutical and Biotechnology.

DeGeeter will publish recommendations on stocks in the specialty pharmaceutical and biotechnology industries with a market capitalization of less than $1.5 billion. His coverage universe focuses on rheumatology, infectious disease and anti-infective drugs.

The company also recently appointed Michael Rindos as the firm's director of research. He will cover stocks in the technology and telecommunications sectors, focusing on asset tracking, wireless services, security devices and related industries.

H.C. Wainwright is a privately held investment bank based in New York.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.